Newsstand | Page 11 | Aplastic Anemia & MDS International Foundation Return to top.


Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Expanded Choices Emerge for Myelofibrosis Following Ruxolitinib Therapy

Originally Published: 02/28/2020
Ruben Mesa, MD Newly approved and investigational agents are joining ruxolitinib (Jakafi) for the treatment of myelofibrosis (MF) and may provide options for patients who progress or become intolerant to frontline JAK inhibitors. At the 24th Annual International Congress on Hematologic Malignancies, hosted by Physicians’ Education Resource®, LLC, Ruben Mesa, MD, who is director of the UT San Antonio MD Anderson Cancer Center, presented available and emerging therapy options for patients who require additional MF therapy following ruxolitinib. (continued)

What's-New: Foundation Update Newsletter February 2020

Originally Published: 02/17/2020
To find inside: NEW Find a Specialist Page NEW Patient & Family Conference, Atlanta March For Marrow 11th Anniversaries in The Highlands, TX and Long Beach, CA NEW MDS Patient Guide NEW Home for Recorded Webinars NEW Patient Story Clinical Trial, Rare Disease Day 2020, and more!

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia

Originally Published: 02/13/2020
Key Points In patients with newly diagnosed mIDH1 AML (median age, 76 years), ivosidenib monotherapy achieved median overall survival of 12.6 months. The CR/CRh rate was 42.4%; mutation clearance in 64% patients with CR/CRh suggests that ivosidenib alters the biology of mIDH1 AML. (continued at link)

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Originally Published: 02/06/2020
Abstract TP53 mutations are associated with adverse outcomes and shorter response to hypomethylating agents (HMAs) in myelodysplastic syndrome (MDS). Limited data have evaluated the impact of the type, number, and patterns of TP53 mutations in response outcomes and prognosis of MDS. We evaluated the clinicopathologic characteristics, outcomes, and response to therapy of 261 patients with MDS and TP53 mutations. Median age was 68 years (range, 18-80 years). A total of 217 patients (83%) had a complex karyotype. TP53 mutations were detected at a median variant allele frequency (VAF) of 0.39 (...

OncLive Peer Exchange: Diagnosis of Myelodysplastic Syndrome

Originally Published: 01/29/2020
The panel provides perspective on the diagnosis of MDS, or Myelodysplastic Syndromes.  They discuss recent innovation, including next-gen testing to enhance the efficacy of treatments.  Watch these experts here!

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Originally Published: 01/09/2020
Abstract BACKGROUND Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally become dependent on red-cell transfusions. Luspatercept, a recombinant fusion protein that binds transforming growth factor β superfamily ligands to reduce SMAD2 and SMAD3 signaling, showed promising results in a phase 2 study.   (continued) 

Iron Chelation Therapy May Improve Overall Survival in Patients With Myelodysplastic Syndrome

Originally Published: 01/02/2020
Iron chelation therapy may reduce mortality and leukemia transformation risk among patients with myelodysplastic syndrome (MDS), according to a meta-analysis published in Clinical and Experimental Medicine. Anemia is a common issue among patients with MDS. Red blood cell transfusion can be used to treat anemia in these patients but can also lead to iron overload, which is exacerbated by unrestrained intestinal iron uptake. Iron chelation therapy is sometimes administered to patients with MDS when iron overload occurs, but there is debate as to whether this is a sufficiently safe and...

AML Research Efforts in Full Swing After Decades of Stagnation

Originally Published: 12/27/2019
After decades of few advances and stagnant treatment approaches, which mainly comprised 7+3 chemotherapy, the acute myeloid leukemia (AML) paradigm now has several agents approved, and plenty of ongoing trials are exploring other novel therapies alone and in combination, according to Melissa L. Larson, MD. Several of these research efforts are focused on targeting molecular drivers of disease, such as FLT3 and IDH1/2 mutations.

The Falling, Wandering and Crashing Business of Cancer Treatment Side Effects

Originally Published: 12/26/2019
With neuropathy as a result of treatment comes a whole host of issues. The first one I can think of? Oops, there goes the wine! In more ways than one, actually, as wine is probably one of the last things you can enjoy while undergoing chemo. And not only can you not enjoy it, but when you try to lift that glass onto your kitchen counter, neuropathy will cause you to instead bash it against the edge. Hopefully this was not your special glass. If you try it again while in treatment, pick the cheap old glass you got at a yard sale. No big loss. The bashing goes on for a while but it does get...

Woyach Highlights Progress and Next Steps in CLL Paradigm

Originally Published: 12/26/2019
With therapeutic additions to the treatment paradigm of chronic lymphocytic leukemia (CLL), it is now a question of which regimen to give patients in the frontline setting, explained Jennifer A. Woyach, MD. “In the frontline setting, our new options for targeted therapy include ibrutinib (Imbruvica), acalabrutinib (Calquence), and venetoclax (Venclexta) plus obinutuzumab (Gazyva). We have 3 great targeted therapy options. One of the difficulties right now is that we have such great options. [Which patient] do we choose for which agent?” said Woyach.
Share with